QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:GRPH

Graphite Bio (GRPH) Stock Forecast, Price & News

$2.97
+0.05 (+1.71%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.87
$2.97
50-Day Range
$2.41
$3.38
52-Week Range
$1.59
$4.48
Volume
106,973 shs
Average Volume
226,566 shs
Market Capitalization
$172.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.33

Graphite Bio MarketRank™ Forecast

Analyst Rating
Hold
1.89 Rating Score
Upside/​Downside
12.2% Upside
$3.33 Price Target
Short Interest
Healthy
2.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.05) to ($0.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

779th out of 983 stocks

Biological Products, Except Diagnostic Industry

128th out of 164 stocks


GRPH stock logo

About Graphite Bio (NASDAQ:GRPH) Stock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
SVB Securities Sticks to Their Hold Rating for Graphite Bio (GRPH)
U.S. Loses to China in Shocking WAR GAMES
=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
Graphite Bio (NASDAQ:GRPH) Issues Earnings Results
BTIG Sticks to Its Hold Rating for Graphite Bio (GRPH)
Expert Ratings for Graphite Bio
See More Headlines

GRPH Price History

GRPH Company Calendar

Last Earnings
5/11/2023
Today
6/02/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRPH
Fax
N/A
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.33
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+12.2%
Consensus Rating
Hold
Rating Score (0-4)
1.89
Research Coverage
9 Analysts

Profitability

Net Income
$-101,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.75 per share

Miscellaneous

Free Float
35,762,000
Market Cap
$172.56 million
Optionable
Not Optionable
Beta
0.09

Key Executives

  • Dr. Joshua Lehrer-Graiwer FACC (Age 48)
    M.D., Pres, CEO & Director
    Comp: $724.58k
  • Dr. Matthew Porteus M.D. (Age 57)
    Ph.D., Academic Founder & Director
    Comp: $90.77k
  • Dr. Maria Grazia Roncarolo M.D. (Age 68)
    Ph.D., Academic Founder & Chair of Scientific Advisory Board
    Comp: $70k
  • Mr. Philip P. Gutry (Age 49)
    Chief Bus. Officer
    Comp: $541.33k
  • Dr. Daniel Dever Ph.D.
    Co-Founder & Head of Discovery Research
  • Ms. Alethia Rene Young (Age 43)
    Chief Financial Officer
  • Dr. Christine Garrett P.M.P. (Age 51)
    Ph.D., Chief of Staff & Sr. VP of Operations
  • Mr. Jerry Cacia (Age 55)
    Chief Technical Officer
  • Dr. Jane Grogan Ph.D. (Age 54)
    Chief Scientific Officer
  • Stephanie Yao
    VP of Communications & Investor Relations













GRPH Stock - Frequently Asked Questions

Should I buy or sell Graphite Bio stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Graphite Bio in the last twelve months. There are currently 1 sell rating and 8 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRPH, but not buy additional shares or sell existing shares.
View GRPH analyst ratings
or view top-rated stocks.

What is Graphite Bio's stock price forecast for 2023?

9 brokerages have issued twelve-month price targets for Graphite Bio's shares. Their GRPH share price forecasts range from $2.00 to $7.00. On average, they predict the company's share price to reach $3.33 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price.
View analysts price targets for GRPH
or view top-rated stocks among Wall Street analysts.

How have GRPH shares performed in 2023?

Graphite Bio's stock was trading at $3.32 at the beginning of 2023. Since then, GRPH stock has decreased by 10.5% and is now trading at $2.97.
View the best growth stocks for 2023 here
.

When is Graphite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GRPH earnings forecast
.

How were Graphite Bio's earnings last quarter?

Graphite Bio, Inc. (NASDAQ:GRPH) released its earnings results on Thursday, May, 11th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.08.

When did Graphite Bio IPO?

(GRPH) raised $224 million in an IPO on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share.

What is Graphite Bio's stock symbol?

Graphite Bio trades on the NASDAQ under the ticker symbol "GRPH."

Who are Graphite Bio's major shareholders?

Graphite Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (14.67%), K2 Principal Fund L.P. (1.67%), Prosight Management LP (1.51%), Board of Trustees of The Leland Stanford Junior University (1.21%), BlackRock Inc. (0.87%) and Federated Hermes Inc. (0.70%). Insiders that own company stock include Biocapital LP Samsara and Phil Gutry.
View institutional ownership trends
.

How do I buy shares of Graphite Bio?

Shares of GRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Graphite Bio's stock price today?

One share of GRPH stock can currently be purchased for approximately $2.97.

How much money does Graphite Bio make?

Graphite Bio (NASDAQ:GRPH) has a market capitalization of $172.56 million. The company earns $-101,050,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How can I contact Graphite Bio?

The official website for the company is www.graphitebio.com. The company can be reached via phone at 650-484-0886 or via email at ir@graphitebio.com.

This page (NASDAQ:GRPH) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -